Safety and Efficacy of BC LisPram

Inclusion Criteria: * Males and females ≥ 18 years of age. * Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed. * Insulin pump therapy for at least 3 months, with daily insulin needs ranging between 30 and 80 U. * Most recent HbA1c ≤ 9.5% (over the last two months). * Effective birth control in female participants of childbearing potential. Medically acceptable contraception methods include condom, pills, and intrauterine device. Exclusion Criteria: * Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc....). * Current use of glucocorticoid medication. * Use of medication that alters gastrointestinal motility. * Planned or ongoing pregnancy. * Breastfeeding individuals * Severe hypoglycemic episode within one month of admission. * Severe diabetic ketoacidosis episode within one month of admission. * Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. * Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. * Known hypersensitivity to any of the study drugs or their excipients. * Allergy to paracetamol (acetaminophen). * Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. * Clinically abnormal significant values for haemato, biochemistry, or urinalysis screening test as judged by the Principle Investigator for underlying disease. * Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).